Our study provides evidence SSG can be used an immune adjuvant not only as a protein tyrosine phosphatase inhibitor in treatment of cancer patients, but also for recruiting the immune cells to the right place in fighting cancer cells in patients with ascites and pleural effusion with PD1 or PD-L1. Here, CD274 is linked to cancer.